Novel pathway for somatostatin analogs in patients with acromegaly

Trends in Endocrinology and Metabolism

Volumn 24, Issue 5, 2013, Pages 238-246

  Gadelha, Mônica R ^a   Kasuki, Leandro ^a   Korbonits, Márta ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; AROMATIC HYDROCARBON RECEPTOR; ARYL HYDROCARBON RECEPTOR INTERACTING PROTEIN; CABERGOLINE; GROWTH HORMONE; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; SOMATOMEDIN C; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; TEMOZOLOMIDE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ACROMEGALY; DISEASE ACTIVITY; DRUG MECHANISM; GENE MUTATION; GENE PRODUCT; GERM LINE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TRANSSPHENOIDAL SURGERY; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; ZAC1 GENE;

ACROMEGALY; ANIMALS; CELL CYCLE PROTEINS; COMBINED MODALITY THERAPY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; MODELS, BIOLOGICAL; PITUITARY GLAND; SIGNAL TRANSDUCTION; SOMATOSTATIN; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84876986891     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.11.007     Document Type: Review

References (100)

1. Melmed S. Medical progress: acromegaly. N. Engl. J. Med. 2006, 355:2558-2573.
2. Colao A., et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 2004, 25:102-152.
3. Holdaway I.M., et al. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 2008, 159:89-95.
4. Tita P., et al. High prevalence of differentiated thyroid carcinoma in acromegaly. Clin. Endocrinol. (Oxf.) 2005, 63:161-167.
5. Melmed S., et al. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 2009, 94:1509-1517.
6. Morin E., et al. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary 2012, 15:97-100.
7. Bression D., et al. Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifusion system. J. Clin. Endocrinol. Metab. 1982, 55:589-593.
8. Sandret L., et al. Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 2011, 96:1327-1335.
9. Mattar P., et al. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling IGF-I levels in acromegaly. Neuroendocrinology 2010, 92:120-127.
10. Buchfelder M., et al. The German ACROSTUDY: past and present. Eur. J. Endocrinol. 2009, 161(Suppl. 1):S3-S10.
11. van der Lely A.J., et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J. Clin. Endocrinol. Metab. 2012, 97:1589-1597.
12. Neggers S.J., et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J. Clin. Endocrinol. Metab. 2007, 92:4598-4601.
13. Freda P.U., et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 2005, 90:4465-4473.
14. Mercado M., et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin. Endocrinol. (Oxf.) 2007, 66:859-868.
15. Melmed S., et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 2010, 13:18-28.
16. Ben-Shlomo A., Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol. Metab. 2010, 21:123-133.
17. Patel Y.C. Somatostatin and its receptor family. Front. Neuroendocrinol. 1999, 20:157-198.
18. Neto L.V., et al. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J. Clin. Endocrinol. Metab. 2009, 94:1931-1937.
19. Taboada G.F., et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur. J. Endocrinol. 2008, 158:295-303.
20. Duran-Prado M., et al. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J. Clin. Endocrinol. Metab. 2009, 94:2634-2643.
21. Panetta R., Patel Y.C. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci. 1995, 56:333-342.
22. Ferone D., et al. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J. Clin. Endocrinol. Metab. 2008, 93:1412-1417.
23. Wildemberg, L.E. et al. (2012) Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2, expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J. Endocrinol. Invest. http://www.jendocrinolinvest.it/jei/en/abstract.cfm%3Farticolo_id=8305.
24. Gatto F., et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 2012, 10.1210/jc.2012-2609.
25. Grozinsky-Glasberg S., et al. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr. Relat. Cancer 2008, 15:701-720.
26. Cakir M., et al. Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1 - molecular pathways. J. Cell. Mol. Med. 2010, 14:2570-2584.
27. Cervia D., Bagnoli P. An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology. Pharmacol. Ther. 2007, 116:322-341.
28. Colao A., et al. Resistance to somatostatin analogs in acromegaly. Endocr. Rev. 2011, 32:247-271.
29. Grant M., et al. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol. Endocrinol. 2008, 22:2278-2292.
30. Duran-Prado M., et al. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J. Clin. Endocrinol. Metab. 2010, 95:2497-2502.
31. Duran-Prado M., et al. The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Oncogene 2012, 31:2049-2061.
32. Ballare E., et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J. Clin. Endocrinol. Metab. 2001, 86:3809-3814.
33. Filopanti M., et al. Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. J. Clin. Endocrinol. Metab. 2005, 90:4824-4828.
34. Fougner S.L., et al. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J. Clin. Endocrinol. Metab. 2010, 95:2334-2342.
35. Fougner S.L., et al. Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. J. Clin. Endocrinol. Metab. 2008, 93:1211-1216.
36. Barlier A., et al. Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. J. Clin. Endocrinol. Metab. 1998, 83:1604-1610.
37. Obari A., et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr. Pathol. 2008, 19:82-91.
38. Fougner S.L., et al. Adenoma granulation pattern correlates to clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin. Endocrinol. (Oxf.) 2012, 96-102.
39. Kato M., et al. Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr. J. 2012, 59:221-228.
40. Bhayana S., et al. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J. Clin. Endocrinol. Metab. 2005, 90:6290-6295.
41. Heck A., et al. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin. Endocrinol. (Oxf.) 2012, 77:72-78.
42. Fusco A., et al. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 2008, 93:2746-2750.
43. Engstrom E.B., et al. Men with acromegaly need higher doses of octreotide than women. Clin. Endocrinol. (Oxf.) 2002, 56:73-77.
44. Suliman M., et al. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. J. Endocrinol. Invest. 1999, 22:409-418.
45. Newman C.B., et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. J. Clin. Endocrinol. Metab. 1995, 80:2768-2775.
46. Gilbert J.A., et al. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clin. Endocrinol. (Oxf.) 2005, 62:742-747.
47. Taboada G.F., et al. Acute test with subcutaneous octreotide as a predictor of the response to treatment with octreotide LAR. Arq. Bras. Endocrinol. Metabol. 2005, 49:390-395. (in Portuguese).
48. Georgitsi M., et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:4101-4105.
49. Chahal H.S., et al. AIP mutation in pituitary adenomas in the 18th century and today. N. Engl. J. Med. 2011, 364:43-50.
50. Chahal H.S., et al. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol. Metab. 2010, 21:419-427.
51. Igreja S., et al. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum. Mutat. 2010, 31:950-960.
52. Vierimaa O., et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312:1228-1230.
53. Daly A.F., et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J. Clin. Endocrinol. Metab. 2007, 92:1891-1896.
54. Beckers A., Daly A.F. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur. J. Endocrinol. 2007, 157:371-382.
55. Leontiou C.A., et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 2008, 93:2390-2401.
56. Cazabat L., et al. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J. Clin. Endocrinol. Metab. 2012, 97:E663-E670.
57. Tichomirowa M.A., et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur. J. Endocrinol. 2011, 165:509-515.
58. Daly A.F., et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J. Clin. Endocrinol. Metab. 2010, 95:E373-E383.
59. Barlier A., et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 2007, 92:1952-1955.
60. Jaffrain-Rea M.L., et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr. Relat. Cancer 2009, 16:1029-1043.
61. Gadelha M.R., et al. Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12. J. Clin. Endocrinol. Metab. 2000, 85:707-714.
62. Gadelha M.R., et al. Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. J. Clin. Endocrinol. Metab. 1999, 84:249-256.
63. Raitila A., et al. Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression. Am. J. Pathol. 2010, 177:1969-1976.
64. Trivellin G., Korbonits M. AIP and its interacting partners. J. Endocrinol. 2011, 210:137-155.
65. Cain J.W., et al. Role of the aryl hydrocarbon receptor-interacting protein in familial isolated pituitary adenoma. Expert Rev. Endocrinol. Metab. 2010, 5:681-695.
66. Pinho L.K., et al. Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening. Arq. Bras. Endocrinol. Metabol. 2010, 54:698-704.
67. Stratakis C.A., et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin. Genet. 2010, 78:457-463.
68. Kasuki L., et al. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr. Relat. Cancer 2012, 19:L25-L29.
69. Chahal H.S., et al. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J. Clin. Endocrinol. Metab. 2012, 97:E1411-E1420.
70. Jaffrain-Rea M.L., et al. Aryl hydrocarbon receptor interacting protein in somatotroph adenomas: a molecular target for somatostatin analogues?. Endocr. Abstr. 2012, 29:P1343.
71. Kasuki Jomori de Pinho L., et al. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in Somatotropinomas than Ki-67 and p53. Neuroendocrinology 2011, 94:39-48.
72. Theodoropoulou M., et al. ZAC1 target genes and pituitary tumorigenesis. Mol. Cell. Endocrinol. 2010, 326:60-65.
73. Pagotto U., et al. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res. 2000, 60:6794-6799.
74. Theodoropoulou M., et al. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. Int. J. Cancer 2009, 125:2122-2126.
75. Theodoropoulou M., et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 2006, 66:1576-1582.
76. Theodoropoulou M., et al. Aggression and resistance in somatotropinoma: molecular mechanisms. J. Klin. Endokrinol. Stoffw. 2012, 5:76-77.
77. Hollingshead B.D., et al. Endogenous hepatic expression of the hepatitis B virus X-associated protein 2 is adequate for maximal association with aryl hydrocarbon receptor-90-kDa heat shock protein complexes. Mol. Pharmacol. 2006, 70:2096-2107.
78. Heliovaara E., et al. The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas. Am. J. Pathol. 2009, 175:2501-2507.
79. Tentler J.J., et al. Somatostatin acts by inhibiting the cyclic 3',5'-adenosine monophosphate (cAMP)/protein kinase A pathway, cAMP response element-binding protein (CREB) phosphorylation, and CREB transcription potency. Mol. Endocrinol. 1997, 11:859-866.
80. Schonbrunn A. Selective agonism in somatostatin receptor signaling and regulation. Mol. Cell. Endocrinol. 2008, 286:35-39.
81. Tsaneva-Atanasova K., et al. Mechanism of spontaneous and receptor-controlled electrical activity in pituitary somatotrophs: experiments and theory. J. Neurophysiol. 2007, 98:131-144.
82. Barlier A., et al. Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J. Clin. Endocrinol. Metab. 1999, 84:2759-2765.
83. Wood D.F., et al. A comparison of the effects of bromocriptine and somatostatin on growth hormone gene expression in the rat anterior pituitary gland in vitro. Mol. Cell. Endocrinol. 1987, 52:257-261.
84. Gruszka A., et al. Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro. Mol. Cell. Endocrinol. 2012, 362:104-109.
85. Florio T. Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. Mol. Cell. Endocrinol. 2008, 286:40-48.
86. Florio T., et al. The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells. Mol. Endocrinol. 1994, 8:1289-1297.
87. Buscail L., et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:2315-2319.
88. Florio T., et al. Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol. Endocrinol. 1999, 13:24-37.
89. Ostman A., et al. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 2006, 6:307-320.
90. Zatelli M.C., et al. SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma. Endocrinology 2005, 146:2692-2698.
91. Pages P., et al. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. J. Biol. Chem. 1999, 274:15186-15193.
92. Hubina E., et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur. J. Endocrinol. 2006, 155:371-379.
93. Guillermet-Guibert J., et al. Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways. Cell Death Differ. 2007, 14:197-208.
94. Ferrante E., et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr. Relat. Cancer 2006, 13:955-962.
95. Lohrer P., et al. Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro. Neuroendocrinology 2001, 74:95-105.
96. Zatelli M.C., et al. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr. Relat. Cancer 2007, 14:91-102.
97. Watcharasit P., et al. Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:7951-7955.
98. Khattak M.N., et al. CRH and SRIF have opposite effects on the Wnt/beta-catenin signalling pathway through PKA/GSK-3beta in corticotroph pituitary cells. Cancer Invest. 2010, 28:797-805.
99. Chen J.S., et al. Octreotide inhibits growth of colonic cancer SW480 cells by modulating the Wnt/P-catenin pathway. Pharmazie 2009, 64:126-131.
100. Elston M.S., et al. Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology 2008, 149:1235-1242.